Previous 10 |
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two years Results show a comparable 35% reduction from baseline in dyskinesia and OFF was achieved across all subgroups naïve to GOCOVRI as measured by MDS-UPDRS, Pa...
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option to purchase an aggregate of 49,210 shares of the company’...
Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more ...
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) ...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...